15. Is the PG-SGA© a validated instrument?

15. Is the PG-SGA© a validated instrument?

Predictive validity of the PG-SGA© (e.g. significant association with length of hospital stay) has been shown in both cancer patients (Laky et al., 2010) and non-cancer surgery patients (Huang et al., 2014). Furthermore, the PG-SGA© score has been associated with hospital re-admission (Bauer et al., 2002), duration of neutropenic fever in patients with acute leukemia during induction chemotherapy (Esfahani et al., 2013) and quality of life in both cancer patients (Citak et al., 2013; Malihi et al., 2013; Mohammadi et al., 2013; Zalina et al., 2012; Capuano et al., 2010; Shahmoradi et al., 2009; Isenring et al., 2003) and non-cancer patients (Campbell et al., 2008). For the full list of studies that used the PG-SGA© please see the full list of publications here.

Besides the full PG-SGA©, also the PG-SGA Short Form© (also known as abridged PG-SGA©) has been studied. Higher scores on the PG-SGA Short Form© have also been associated with increased length of hospital stay, reduction in chemotherapy (decreased chemo tolerance) and increased mortality (Vigano et al., 2014).